News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Calypte Biomedical Corporation (CYPT) and Maxim Biomedical Announce Joint Distribution of Incidence Testing Assays



4/25/2013 1:25:29 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PORTLAND, Ore., April 25, 2013 (GLOBE NEWSWIRE) -- Calypte Biomedical Corporation (OTCBB:CBMC) and Maxim Biomedical Inc. today announced a reciprocal distribution agreement under which customers may purchase from either company, on the same terms, both Calypte's Aware™ BED EIA HIV-1 Incidence Test and Maxim's HIV-1 Limiting Antigen (LAg)-Avidity EIA Kit.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES